Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 10,000 Shares

Inhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe bought 10,000 shares of Inhibrx stock in a transaction that occurred on Thursday, August 29th. The stock was purchased at an average price of $14.03 per share, with a total value of $140,300.00. Following the purchase, the chief executive officer now directly owns 135,000 shares in the company, valued at $1,894,050. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mark Lappe also recently made the following trade(s):

• On Tuesday, September 3rd, Mark Lappe acquired 20,000 shares of Inhibrx stock. The stock was purchased at an average cost of $15.81 per share, for a total transaction of $316,200.00.

Inhibrx Price Performance

Shares of Inhibrx stock opened at $16.04 on Thursday. The firm has a fifty day moving average price of $13.38 and a 200 day moving average price of $24.96. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $18.95.

Inhibrx (NASDAQ:INBX) last released its quarterly earnings data on Tuesday, August 13th. The company reported $125.48 earnings per share for the quarter, beating analysts’ consensus estimates of ($3.60) by $129.08. The company had revenue of $0.10 million for the quarter. As a group, equities analysts expect that Inhibrx, Inc. will post 87.5 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AJOVista LLC acquired a new position in shares of Inhibrx in the 4th quarter valued at $26,000. Quadrant Capital Group LLC purchased a new position in Inhibrx in the fourth quarter valued at $26,000. E Fund Management Co. Ltd. acquired a new position in shares of Inhibrx in the fourth quarter worth about $209,000. HCR Wealth Advisors purchased a new stake in shares of Inhibrx during the 4th quarter worth about $239,000. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Inhibrx by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,106 shares of the company’s stock valued at $318,000 after acquiring an additional 3,635 shares during the period. 82.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, JMP Securities assumed coverage on Inhibrx in a research report on Tuesday, July 23rd. They issued a “market perform” rating on the stock.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.